Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia
Clinical and Applied Thrombosis/Hemostasis · 2026
DOI: 10.1177/10760296261462870 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2026. Verfasst von Sercan Olcar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Extracellular Traps, Histones, Thrombosis, Hemostasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Neutrophil extracellular trap (NET) formation has emerged as a key driver of thrombosis in myeloproliferative neoplasms (MPNs). Its role in congenital bleeding disorders, however, remains unexplored.
Objectives
To investigate circulating citrullinated histone H3 (cit-H3), a marker of NETosis, in thrombosis-prone MPNs and bleeding-prone severe hemophilia A.
Methods
In a cross-sectional study, plasma cit-H3 was quantified by ELISA in patients with JAK2-mutated polycythemia vera or essential thrombocythemia, patients with severe hemophilia A, and matched healthy controls. Clinical and laboratory data were analyzed for associations with cit-H3 levels.
Results
Eighty-nine participants were included: 26 with myeloproliferative neoplasms (MPNs), 31 with severe hemophilia A, and 32 healthy controls. Demographic characteristics were comparable across groups, though comorbidities were more frequent in MPNs. Laboratory analyses confirmed expected disease-specific differences, including elevated leukocyte, neutrophil, and platelet counts in MPNs and prolonged activated partial thromboplastin time in hemophilia A. Circulating citrullinated histone H3 (cit-H3) levels differed significantly among groups (p < 0.001), being lowest in controls, intermediate in MPNs, and highest in hemophilia A. Within disease groups, cit-H3 levels were unaffected by clinical variables such as MPN subtype, aspirin use, phlebotomy history, or factor replacement regimen.
Conclusions
Elevated circulating cit-H3 levels, suggestive of increased NETosis activity, were observed in both thrombosis-prone MPNs and bleeding-prone hemophilia A. These exploratory findings suggest a possible association between NET formation and thromboinflammatory processes across distinct hemostatic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
- Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
- Department of Biochemistry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
ORCID-Profile: Sercan Olcar, Ahmet Emre Eşkazan, Muhlis Cem Ar
Zitieren
APA
Olcar, S., Elverdi, T., Bolayırlı, İ. M., Eşkazan, A. E., Özmen, D., Özer Çerme, M. D., Salihoğlu, A., Başlar, Z., & Ar, M. C. (2026). Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296261462870
Vancouver
Olcar S, Elverdi T, Bolayırlı İM, Eşkazan AE, Özmen D, Özer Çerme MD, et al. Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia. Clinical and Applied Thrombosis/Hemostasis. 2026. doi:10.1177/10760296261462870
BibTeX
@article{Olcar2026,
author = {Olcar, Sercan and Elverdi, Tuğrul and Bolayırlı, İbrahim Murat and Eşkazan, Ahmet Emre and Özmen, Deniz and Özer Çerme, Melis Dila and Salihoğlu, Ayşe and Başlar, Zafer and Ar, Muhlis Cem},
title = {Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
doi = {10.1177/10760296261462870}
}
EUVIMED